GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Size: px
Start display at page:

Download "GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: Study Number: Title: A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Compared to (PM ) (Short title: LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and modify outcomes after an acute coronary syndrome [(LATITUDE)-TIMI 60] Rationale: This Phase III outcomes trial compared the effects of losmapimod 7.5 mg twice daily (BID) for 12 weeks versus placebo when added to standard of care on the incidence of major adverse cardiovascular events (MACE) in subjects with acute coronary syndrome (ACS) (non-st-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]). Phase: Phase III Study Period: 03 Jun Dec 2015 Study Design: This was a randomized, placebo-controlled, double-blind, parallel-group, multicenter international study which was designed to be conducted in two parts. The entire trial was planned to include approximately 25,500 subjects presenting with NSTEMI or STEMI. Subjects were to be randomized 1:1 to receive either oral losmapimod or matching placebo BID for 12 weeks in addition to standard of care. They were to be followed for an additional 12 weeks after completing treatment, for a total study duration of 24 weeks. An independent data monitoring committee (IDMC) had study oversight to ensure scientific integrity of the data and subject safety, and an independent Clinical Events Committee (CEC) blinded to treatment adjudicated outcome events. The study was planned in two parts (Part A and Part B): Part A: A leading cohort of 3,500 subjects was randomized to provide an initial assessment of safety and exploratory efficacy (~200 adjudicated primary endpoint events) before progressing to Part B. Efficacy data from this stage of the study was not planned to be used in the primary efficacy analysis of the trial. Part B: The main cohort was planned to be event driven with approximately 22,000 subjects randomized to provide the main assessment of efficacy with an event target of 1,400 adjudicated primary endpoint events and 1,000 1,200 adjudicated cardiovascular (CV) death and myocardial infarction (MI) events. As prespecified in the protocol, upon completion of the treatment phase of Part A summary level unblinded efficacy and safety data from Part A were reviewed by a limited group involved in study conduct (comprising trial leadership from the Sponsor and the Thrombolysis in Myocardial Infarction (TIMI) Study Group) in order to determine whether to progress to Part B of the trial. A decision was made not to progress to Part B of the study, based on lack of efficacy on the primary endpoint, with acceptable safety profile. The trial was completed at the end of Part A. Centres: Argentina 6, Australia 10, Belgium 10, Bulgaria 7, Canada 9, Chile 4, Czech Republic 11, Denmark 4, Estonia 3, France 10, Germany 24, Greece 6, Hong Kong 3, Hungary 5, Israel 5, Italy 7, Republic of Korea 8, Mexico 2, Netherlands 14, New Zealand 6, Norway 5, Philippines 4, Poland 13, Romania 3, Russian Federation 20, Slovakia 4, South Africa 7, Spain 12, Sweden 8, Taiwan 5, Thailand 4, Ukraine 7, United Kingdom 6, United States 70 Indication: Acute coronary syndrome Treatment: : 7.5 mg/tablet/oral; 1 tablet within 2 hours after randomization (and subsequently 1 tablet every 12 hours) for 12 weeks duration. : 0 mg/tablet/oral; 1 tablet within 2 hours after randomization (and subsequently 1 tablet every 12 hours) for 12 weeks duration. Objectives: The primary objective was to evaluate the efficacy of oral losmapimod compared to placebo when added to standard of care in subjects with ACS on the time to first occurrence of adjudicated MACE (defined as cardiovascular [CV] death, myocardial infarction [MI], or severe recurrent ischemia requiring urgent coronary revascularization [SRI-UR]) through 12 weeks of therapy. Primary Outcome (Endpoints)/Efficacy: The primary efficacy endpoint was the composite measure of adjudicated MACE that includes the time to first occurrence of CV death, MI, or SRI-UR. 1

2 Secondary Outcome (Endpoints)/Efficacy: Principal Secondary Endpoint: The principal secondary endpoint was the time to first occurrence of the composite of adjudicated CV death or MI. Additional Secondary Endpoints: The composite of CV death, MI, or hospitalization for heart failure (HF). The expanded composite of arterial CV events, defined as CV death, MI, SRI-UR, or stroke. The composite of coronary events (defined as coronary heart disease [CHD] death, MI, SRI-UR, or any unplanned coronary artery revascularization). Planned coronary artery revascularizations are those initial or staged interventions performed based on the initial qualifying ACS. The composite of CV death or hospitalization for HF. The composite of CV death, MI or stroke. The composite of CV death, MI, SRI-UR, stroke or hospitalisation for HF. The primary and principal secondary endpoints were evaluated replacing CV death separately with CHD death ( Coronary MACE ) and all-cause death. The primary and principal secondary endpoints were evaluated replacing all MI with Type 1 (spontaneous) MI. Individual components of the composite endpoints (including all-cause mortality). Definite or probable stent thrombosis. Any re-hospitalization within 30 days of discharge. For the primary and each of the secondary endpoints, the principal analysis was through 12 weeks, with additional analyses through 4 and 24 weeks unless otherwise stated. In addition, a recurrent event analysis (i.e. accounting for subjects who experienced multiple events) was conducted for each composite endpoint. Statistical Methods: In total, approximately 25,500 ACS subjects were planned to be recruited, comprising 3,500 subjects in a leading cohort (Part A) used to provide an initial assessment of safety and exploratory efficacy with approximately 200 MACE (defined as CV death, MI, or SRI-UR), followed by a main cohort of approximately 22,000 subjects (event target of 1,400 MACE and 1,000 1,200 CV death or MI). The pivotal and powered assessment of efficacy would have been provided by Part B of the study, with Part A providing an exploratory assessment to support continuation to Part B. Whilst an exploratory cohort could not be appropriately powered for formal assessment of efficacy, the precision with which the MACE effect size could be estimated from Part A was considered. Given the limitations on precision that would be expected in an exploratory context, the decision not to progress to Part B was multifaceted. The principal efficacy evaluation occurred through Week 12 with additional evaluations of efficacy through Weeks 4 and Week 24. The primary analysis of MACE at 12 weeks was based on a stratified log-rank test with a stratified Coxregression model used to estimate the hazard ratio (HR) and its 95% confidence interval (CI) (both analyses stratified by NSTEMI/STEMI). Key secondary endpoints were assessed using the same methods as the primary endpoint. The primary population for all analyses of MACE, secondary time-to-event outcomes, and other efficacy assessments was the All Randomized (Intent-to-Treat [ITT]) Population. Subjects were analysed according to the treatment to which they were randomized. The primary population for evaluation of safety was based on all randomized subjects who received at least one dose of investigational product (IP). Subjects were analysed according to the treatment which they actually received. Study Population: Subjects were eligible for enrollment if they were aged 35 years or older; had been hospitalized with a presumed spontaneous (type 1) MI, including NSTEMI within 24 hours of ischemic symptoms or STEMI within 12 hours of onset; and had at least 1 additional predictor of cardiovascular risk. Study drug was to be administered as early as possible during hospitalization and prior to coronary revascularization or reperfusion. Relevant exclusion criteria at study entry included clinical instability, known acute or chronic liver disease, current life-threatening or opportunistic infection, severe renal impairment (estimated glomerular filtration rate <30 ml/min/1.73 m2), or New York Heart Association class III or IV or Killip class III or IV heart failure at randomization. 2

3 Part A Total Number of Subjects: Planned, N Randomised, N Excluded from analysis ITT population, N Completed as planned, n (%) 1512 (86.0) 1456 (84.1) 2968 (85.1) Never received IP, n (%) 6 (0.3) 7 (0.4) 13 (0.4) Discontinued study treatment, n (%) 240 (13.7) 268 (15.5) 508 (14.6) Withdrawn due to adverse events (AEs), n (%) 66 (3.8) 73 (4.2) 139 (4.0) Withdrawn for other reasons, n (%) 174 (9.9) 195 (11.3) 369 (10.6) Demographics N (ITT) Females: Males 532: : : 2457 Mean age, years (SD) 66.5 (9.72) 66.7 (10.00) 66.6 (9.86) Mean body mass index, kg/m 2 (SD) (5.069) (5.118) (5.093) Race, n (%) Black 25 (1.4) 20 (1.2) 45 (1.3) Central/South/South East Asian 30 (1.7) 34 (2.0) 64 (1.8) East Asian/Japanese 68 (3.9) 71 (4.1) 139 (4.0) White 1614 (92.0) 1585 (91.6) 3199 (91.8) Other 18 (1.0) 21 (1.2) 39 (1.1) Ethnicity, n (%) Hispanic or Latino 75 (4.3) 71 (4.1) 146 (4.2) Not Hispanic or Latino 1682 (95.7) 1660 (95.9) 3342 (95.8) 1. Subjects excluded from analysis due to data integrity issues. Primary Efficacy Results: Time to First Occurrence of MACE Through Week 12 (Day 84) and Week 24 (Day 182) (ITT Population) 1 N=1758 N=1731 n (%) n (%) Week 12 First occurrence MACE 123 (7.0) 139 (8.0) Hazard ratio for losmapimod: placebo % CI 2 (0.91, 1.47) P-value Cardiovascular death 34 (1.9) 31 (1.8) Myocardial infarction 74 (4.2) 90 (5.2) SRI-UR 15 (0.9) 18 (1.0) Week 24 First occurrence MACE, n (%) 162 (9.2) 176 (10.2) Hazard ratio for losmapimod: placebo % CI 2 (0.90, 1.38) P-value Cardiovascular Death 45 (2.6) 38 (2.2) Myocardial infarction 98 (5.6) 117 (6.8) SRI-UR 19 (1.1) 21 (1.2) 1. Analysis was not performed for Week 4 and recurrent analysis was not performed because this was planned for the full study and not for Part A alone. 2. Hazard ratio and CI were estimated using a Cox proportional hazard regression model stratified by baseline STEMI/NSTEMI status with treatment as the only covariate. A hazard ratio <1 indicates a lower risk with the treatment compared with placebo. 3

4 Secondary Outcome Results: Summary of Composite Secondary Efficacy Endpoints Through Week 12 and Week 24 (ITT Population) 1 N=1758 N=1731 Hazard ratio First Occurrence of Time point n (%) n (%) [95% CI] 2 P-value Principal secondary endpoint: CV Week (6.3) 122 (7.0) 1.13 [0.88,1.47] death or MI Week (8.2) 156 (9.0) 1.10 [0.88, 1.38] CV death, MI or hospitalization Week (7.5) 140 (8.1) 1.09 [0.86, 1.38] for HF Week (9.6) 178 (10.3) ND Arterial CV events: CV death, MI, Week (7.7) 151 (8.7) 1.14 [0.91, 1.44] SRI-UR, or stroke Week (9.9) 190 (11.0) ND CV death or hospitalization for Week (4.1) 64 (3.7) 0.90 [0.64, 1.26] HF Week (5.3) 86 (5.0) 0.92 (0.69, 1.24) CV death, MI or stroke Week (6.9) 134 (7.7) 1.12 [0.88, 1.43] Week (8.9) 170 (9.8) ND CV death, MI, SRI-UR, stroke, or Week (8.8) 169 (9.8) 1.11 [0.90, 139] Hosp for HF Week (11.2) 212 (12.2) ND Coronary events: CHD death, MI, Week (8.2) 152 (8.8) 1.08 [0.86, 1.36] SRI-UR or any unplanned Week (10.6) 194 (11.2) ND coronary artery revascularization CHD death, MI SRI-UR Week (6.8) 133 (7.7) 1.14 [0.89, 1.47] Week (8.6) 167 (9.6) ND CHD death or MI Week (6.0) 116 (6.7) 1.12 [0.86, 1.46] Week (7.7) 147 (8.5) ND All cause death, MI SRI-UR Week (7.3) 142 (7.7) 1.14 [0.89, 1.47] Week (9.6) 185 (10.7) ND All cause death, MI Week (6.5) 125 (7.2) 1.11 [0.86, 1.43] Week (8.6) 165 (9.5) ND CV death, Type I (spontaneous) Week (4.9) 94 (5.4) 1.11 [0.83, 1.49] MI or SRI-UR Week (6.9) 127 (7.3) ND CV death, Type I (spontaneous) Week (4.2) 77 (4.4) 1.07 [0.78, 1.48] MI Week (5.9) 106 (6.1) ND All cause mortality Week (2.8) 39 (2.3) 0.80 [0.53, 1.22] Week (3.9) 57 (3.3) ND CV death Week (2.5) 36 (2.1) 0.83 [0.53, 1.28] Week (3.4) 47 (2.7) 0.80 (0.55, 1.18) CHD death Week (2.5) 30 (2.1) 0.76 [0.47, 1.22] Week (2.8) 37 (2.1) ND Myocardial infarction (fatal and Week (4.3) 90 (5.2) 1.23 [0.91, 1.67] non-fatal) Week (5.6) 117 (6.8) 1.21 (0.93, 1.58) Type 1 MI Week (1.8) 42 (2.4) 1.34 [0.85, 2.12] Week (2.9) 62 (3.6) ND SRI-UR Week (0.9) 18 (1.0) 1.14 [0.85, 2.24] Week (1.3) 22 (1.3) ND Hospitalization for HF Week (2.4) 35(2.0) 0.84 [0.54, 1.32] Week (3.0) 49 (2.8) 0.94 (0.63,1.38) Stroke Week (0.9) 14 (0.8) 0.95 [0.46, 1.96] Week (1.1) 18 (1.0) ND Any unplanned revascularization Week (3.2) 62 (3.6) 1.11 [0.77, 1.59] Week (4.3) 87 (5.0) ND Definite or probable stent thrombosis Week (1.5) 11 (0.8) 0.57 [0.27, 1.19] Week (1.6) 12 (0.9) ND 4

5 N=1758 N=1731 Odds ratio Time point n (%) n (%) [95% CI] 3 P-value Re-hospitalization or died within 30 days of discharge NA 42 (2.4) 36 (2.1) 1.03 [0.84, 1.27] NA: not applicable. ND: not determined (not tested). 1. Analysis was not performed for Week 4 and recurrent analysis was not performed because this was planned for the full study and not for Part A alone. 2. Hazard ratio and CI were estimated using a Cox proportional hazard regression model stratified by baseline STEMI/NSTEMI status with treatment as the only covariate. A hazard ratio <1 indicates a lower risk with the treatment compared with placebo. 3. Odds ratio and CI were estimated using a logistic regression model stratified by baseline STEMI/NSTEMI status with treatment as the only covariate. An odds ratio <1 indicates a lower risk with the treatment compared with placebo. Safety Results: Non-serious adverse events (AEs) were collected from the time of the first dose of IP until the Week 12 visit (+2 weeks). Adverse events of special interest were collected from the time of first dose until the Week 24 visit (+/- 2 weeks). Serious adverse events (SAEs) were collected from the time of screening until the Week 24 visit (+/-2 weeks). Summary of On-treatment AEs Excluding Positively CEC-Adjudicated Events (Safety Population) N=1752 N=1724 n (%) n (%) Subjects with any AE on-treatment 972 (55.5) 972 (56.4) Most frequent 10 AEs in each treatment group by Preferred Term: Atrial fibrillation 61 (3.5) 76 (4.4) Angina pectoris 29 (1.7) 48 (2.8) Non-cardiac chest pain 37 (2.1) 46 (2.7) Dyspnoea 54 (3.1) 41 (2.4) Diarrhoea 38 (2.2) 41 (2.4) Cough 31 (1.8) 40 (2.3) Hypotension 32 (1.8) 33 (1.9) Anaemia 28 (1.6) 32 (1.9) Troponin increased 48 (2.7) 31 (1.8) Hypertension 48 (2.7) 30 (1.7) Angina unstable 30 (1.7) 28 (1.6) Headache 29 (1.7) 28 (1.6) Dizziness 29 (1.7) 26 (1.5) On-treatment AEs include those events that occurred on or after the treatment start date and on or before the treatment stop date +3 days, including AEs that occurred during temporary interruptions. 5

6 Summary of SAEs (Fatal and Non-Fatal) Excluding Positively CEC-Adjudicated Events Through Week 24 (Safety Population) N=1752 N=1724 n (%) [related] n (%) [related] Subjects with any SAE through Week 24 (fatal and non-fatal events) 323 (18.4) [15] 363 (21.1) [12] Most frequent 10 SAEs in each group by preferred term: Angina unstable 24 (1.4) [0] 26 (1.5) [0] Angina pectoris 14 (0.8) [0] 24 (1.4) [0] Atrial fibrillation 14 (0.8) [0] 19 (1.1) [0] Pneumonia 12 (0.7) [0] 16 (0.9) [0] Non-cardiac chest pain 19 (1.1) [0] 15 (0.9) [0] Musculoskeletal chest pain 4 (0.2) [0] 14 (0.8) [0] Acute kidney injury 9 (0.5) [0] 13 (0.8) [0] Acute myocardial infarction 7 (0.4) [0] 13 (0.8) [1] Cardiac failure 6 (0.3) [0] 10 (0.6) [0] Troponin increased 11 (0.6) [0] 9 (0.5) [0] Pleural effusion 6 (0.3) [0] 9 (0.5) [0] Cardiac failure congestive 5 (0.3) [0] 8 (0.5) [0] Summary of Fatal SAEs Excluding Positively CEC-Adjudicated Events During Entire Study (Safety Population) N=1752 N=1724 n (%) [related] n (%) [related] Subjects with any fatal SAE during total study 10 (0.6) [0] 13 (0.8) [0] Fatal SAEs by preferred term: Death 1 (<0.1) [0] 3 (0.2) [0] Pneumonia 1 (<0.1) [0] 1 (<0.1) [0] Septic shock 1 (<0.1) [0] 1 (<0.1) [0] Colitis 0 (0.0) [0] 1 (<0.1) [0] Injury 0 (0.0) [0] 1 (<0.1) [0] Injury 0 (0.0) [0] 1 (<0.1) [0] Obstructive airways disorder 0 (0.0) [0] 1 (<0.1) [0] Pancreatic carcinoma metastatic 0 (0.0) [0] 1 (<0.1) [0] Pulmonary embolism 0 (0.0) [0] 1 (<0.1) [0] Sepsis 0 (0.0) [0] 1 (<0.1) [0] Urosepsis 0 (0.0) [0] 1 (<0.1) [0] Ventricular tachycardia 0 (0.0) [0] 1 (<0.1) [0] 1 Chronic obstructive pulmonary disease 2 (0.1) [0] 0 (0.0) [0] Colon cancer metastatic 1 (<0.1) [0] 0 (0.0) [0] Gastrointestinal haemorrhage 1 (<0.1) [0] 0 (0.0) [0] Multi organ failure 1 (<0.1) [0] 0 (0.0) [0] Pericarditis 1 (<0.1) [0] 0 (0.0) [0] Pneumonia aspiration 1 (<0.1) [0] 0 (0.0) [0] 1. This subject had 2 SAEs linked to the death. One event was adjudicated as an efficacy endpoint and the other event (ventricular tachycardia) was not. Therefore, this subject is counted in the CEC-adjudicated endpoint of CV death as well as in this summary, which excludes positively CEC adjudicated events. 6

7 Conclusion: A decision was made not to proceed to the second part of the study (Part B) due to lack of efficacy in Part A. Part A analyses revealed the following: The primary endpoint of MACE (CV death, MI, or SRI-UR) occurred by 12 weeks in 123 (7.0%) subjects in the placebo group and 139 (8.1%) subjects in the losmapimod group (hazard ratio [HR]: 1.16; 95% CI: 0.91, 1.47; p=0.24). Results were similar at Week 24 in the overall cohort, with the primary end point having occurred in 10.3% of subjects in the losmapimod group and 9.7% of subjects in the placebo group (HR: 1.11; 95% CI: 0.9, 1.38). Because there was no evidence for efficacy for the primary outcome, all additional analyses were considered exploratory. The time to first occurrence of the key secondary endpoint of cardiovascular death or MI through Week 12 was not significantly different between the 2 treatment groups (HR: 1.13; 95% CI: 0.88, 1.47). None of the other secondary endpoints revealed any effect of losmapimod. On-treatment AEs (excluding CEC-adjudicated cardiovascular events) were reported for 55.5% (972/1752) of subjects on placebo and 56.4% (972/1724) of subjects on losmapimod. Fatal and non-fatal SAEs (excluding CEC-adjudicated cardiovascular events) through Week 24 were reported for 18.4% (323/1752) of subjects in the placebo group and 21.1% (363/1724) of subjects in the losmapimod group. Fatal SAEs (excluding CEC-adjudicated cardiovascular events) were reported for 0.6% (10/1752) of subjects in the placebo group and 0.8% (13/1724) of subjects in the losmapimod group. 7

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf

More information

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy

After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009 Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and

More information

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective? FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause. CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase

More information

Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM

Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM Efficacy by subgroup, and safety when LDL-C

More information

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Clinical Trial Synopsis TL-OPI-516, NCT#

Clinical Trial Synopsis TL-OPI-516, NCT# Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus

More information

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Marc S. Sabatine, MD, MPH on behalf of the PEGASUS-TIMI 54 Executive

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. International co-ordinating investigator Redacted

SYNOPSIS. International co-ordinating investigator Redacted Drug product: Drug substance(s): AZD6140 Document No.: D5130C00002 Edition No.: 01 Study code: D5130C00002 Date: 12 October 2005 SYNOPSIS A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation

More information

SYNOPSIS. Clinical Study Report IM Double-blind Period

SYNOPSIS. Clinical Study Report IM Double-blind Period Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Online Supplementary Data. Country Number of centers Number of patients randomized

Online Supplementary Data. Country Number of centers Number of patients randomized A Randomized, Double-Blind, -Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary- The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,

More information

Summary of Results for Laypersons

Summary of Results for Laypersons What was the Study Called? Summary of Results for Laypersons A Randomized, Double-blind, Parallel-group, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1 Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A

More information

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20

More information

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel

More information

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Secondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who

Secondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s): Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

ClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008

ClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Sanofi-Aventis ClinicalTrials.gov

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect

More information

Sponsor. Novartis. Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Type 2 diabetes.

Sponsor. Novartis. Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Type 2 diabetes. Sponsor Page 1 Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLAF237A2308 Title A multicenter, randomized, double-blind,

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Trial Results Website

Clinical Trial Results Website Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name (sacubitril/valsartan) Trial Indication(s) Chronic heart failure (CHF) with reduced ejection fraction (EF) Protocol Number CB2314 Protocol

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1. Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Trial Synopsis TL-OPI-518, NCT#

Clinical Trial Synopsis TL-OPI-518, NCT# Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride

More information

Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)

Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) W. Schuyler Jones, MD FACC Director, Adult Cardiac Catheterization Laboratory

More information

Statistical Analysis Plan

Statistical Analysis Plan The BALANCED Anaesthesia Study A prospective, randomised clinical trial of two levels of anaesthetic depth on patient outcome after major surgery Protocol Amendment Date: November 2012 Statistical Analysis

More information

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria Safety Results NOT for The following slides were presented to the Investigators Meeting on 22/05/09 and most of them were also presented at the European Stroke Conference on 27/05/09 They are NOT for in

More information

Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis

Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis Scott D. Solomon, MD, Janet Wittes, PhD, Ernest Hawk, MD, MPH for the Celecoxib Cross Trials

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender An overview of suicide statistics This document summarises information about suicide deaths in New Zealand covering up to 13. It does not attempt to explain causes of suicidal behaviour or causes of changes

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

International Co-ordinating investigator None appointed.

International Co-ordinating investigator None appointed. Drug product: Budesonide/formoterol SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0673 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0673 Date: 13 June,

More information

Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford

Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford Oxford Technology Showcase 2016 Big Healthcare Challenges in chronic disease Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford Chronic diseases.. are long-term

More information

Should I use statins?

Should I use statins? I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of

More information

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites. Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and

More information

ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 02/15/2010

ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 02/15/2010 ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 02/15/2010 Grantor: CDER IND/IDE Number: 49,484 Serial Number: 0278 Efficacy & Safety of Dronedarone Versus Amiodarone

More information

Professional International Study Management

Professional International Study Management Professional International Study Management Services Phase I Study Consulting Phase II-IV IV Study Conduct for Drugs and Devices Protocol Design and Development Study Feasibilities Site Identification,

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

mg 25 mg mg 25 mg mg 100 mg 1

mg 25 mg mg 25 mg mg 100 mg 1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual

More information

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University

More information

CPORT E Trial. Atlantic C PORT

CPORT E Trial. Atlantic C PORT CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program

More information

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018 ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.

More information

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of

More information

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La

More information

Myocardial Infarction In Dr.Yahya Kiwan

Myocardial Infarction In Dr.Yahya Kiwan Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial

EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.

More information

Efficacy and Safety Outcomes in 8040 Women Compared with Men with Atrial Fibrillation Treated with Edoxaban vs Warfarin for an Average 2.

Efficacy and Safety Outcomes in 8040 Women Compared with Men with Atrial Fibrillation Treated with Edoxaban vs Warfarin for an Average 2. Efficacy and Safety Outcomes in 8040 Women Compared with 13065 Men with Atrial Fibrillation Treated with Edoxaban vs Warfarin for an Average 2.8 Years RP Giugliano 1, ML O Donoghue 1, CT Ruff 1, P Merlini

More information

The RealiseAF registry:

The RealiseAF registry: The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf

More information

Sponsor. Novartis. Generic Drug Name Vildagliptin. Therapeutic Area of Trial Type 2 Diabetes Mellitus

Sponsor. Novartis. Generic Drug Name Vildagliptin. Therapeutic Area of Trial Type 2 Diabetes Mellitus Sponsor Novartis Generic Drug Name gliptin Therapeutic Area of Trial Type 2 Diabetes Mellitus Approved Indication Galvus is indicated as an adjunct to diet and exercise to improve glycemic control in patients

More information